This is my second independent submission on material from the same supplier.
I want a method I can write down and repeat, not a rule of thumb.
I would rather over-engineer this than discover a problem later, within reason.
So: what is the actual procedure, and which steps matter as opposed to being ritual?
Worth being precise here: start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
| Δ mass (Da) | Most likely cause | Distinguishing feature |
|---|---|---|
| +1 | Deamidation (Asn or Gln) | New peak, slightly earlier retention |
| −17 | Loss of ammonia | Often with deamidation |
| −18 | Dehydration / succinimide | pH-dependent, reversible |
| +16 | Oxidation (Met, Trp) | Earlier retention, light-related |
| −128 | Missing Gln or Lys | Deletion sequence from synthesis |
| 0 | Isomer: racemisation or scrambling | Same mass, shifted retention |
The part that matters: if you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsMost suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 7 Jun 2026 by vialroom — reworded for clarity after a comment
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.